Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: American Well (AMWL), Centene (CNC) and Natera (NTRA)

Tipranks - Tipranks - Wed Feb 18, 6:42AM CST

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on American Well (AMWL – Research Report), Centene (CNC – Research Report) and Natera (NTRA – Research Report).

President's Day Sale - 70% Off

American Well (AMWL)

In a report released today, Jailendra Singh from Truist Financial maintained a Hold rating on American Well. The company’s shares closed last Friday at $5.40, close to its 52-week low of $5.00.

According to TipRanks.com, Singh has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.2% and a 31.6% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Fortrea Holdings Inc., and Medline, Inc. Class A. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for American Well with a $5.33 average price target, which is a 17.1% upside from current levels. In a report issued on February 12, BTIG also maintained a Hold rating on the stock.

See the top stocks recommended by analysts >>

Centene (CNC)

Truist Financial analyst David S Macdonald reiterated a Buy rating on Centene today and set a price target of $47.00. The company’s shares closed last Friday at $40.58.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 10.6% and a 58.2% success rate. Macdonald covers the Healthcare sector, focusing on stocks such as Guardian Pharmacy Services, Inc. Class A, Concentra Group Holdings Parent, Inc., and Ardent Health Partners, Inc. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Centene with a $43.83 average price target, which is a 12.8% upside from current levels. In a report issued on February 9, Barclays also maintained a Buy rating on the stock with a $54.00 price target.

Natera (NTRA)

Piper Sandler analyst David Westenberg reiterated a Buy rating on Natera today and set a price target of $230.00. The company’s shares closed last Friday at $206.23.

According to TipRanks.com, Westenberg is a 4-star analyst with an average return of 11.3% and a 49.8% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

Currently, the analyst consensus on Natera is a Strong Buy with an average price target of $265.45.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).